Abstract
Bispecific heteroconjugated F(ab')2 fragments were prepared from pepsin-digested monoclonal OKT3 (anti-CD3) and 3G8 (anti-CD16) antibodies with 5,5'-dithiobis- (2-nitrobenzoic acid). When these bispecific antibodies (BsA) were added to peripheral blood lymphocyte (PBL) cultures with 100 U/ml human recombinant interleukin-2 (rIL-2), preferable growth of natural killer cells occurred. After 3 weeks the frequencies of CD56+ and CD56+3- cells in cultures with BsA were 74 +/- 7% and 65 +/- 7%, respectively, compared with 48 +/- 6% and 29 +/- 7% in control cultures. The frequencies of CD3+ lymphocytes in the presence of BsA, cells from 1-day cultures were labelled with fluorescein isothiocyanate (FITC)-conjugated anti-CD3, CD4 and CD8 monoclonal antibodies (mAb) and propidium iodide which stains dead cells. Flow cytometry revealed that more than 95% of the dead cells in cultures with BsA were CD3+. Thirty-seven per cent of CD3+, 43% of CD4+ and 17% of CD8+ cells were dead on day 1, and after 3 days the CD4+/CD8+ ratio among viable lymphocytes was 1.6 in the control and 0.5 in BsA cultures. Taken together, these results show that bispecific (anti-CD3 x anti-CD16) F(ab')2 fragments are strongly immunomodulatory by inducing the killing of T cells by CD16+ cells.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bolhuis R. L., Braakman E. Lymphocyte-mediated responses: activation of, and lysis by, cytotoxic lymphocytes. Curr Opin Immunol. 1988 Dec;1(2):236–240. doi: 10.1016/0952-7915(88)90007-6. [DOI] [PubMed] [Google Scholar]
- Daniel V., Schimpf K., Opelz G. Lymphocyte autoantibodies and alloantibodies in HIV-positive haemophilia patients. Clin Exp Immunol. 1989 Feb;75(2):178–183. [PMC free article] [PubMed] [Google Scholar]
- Davignon J. L., Vallin-Davignon M., Cohen P. L., Eisenberg R. A. Targeting of T-B interaction using heteroconjugate antibody. Immunology. 1991 May;73(1):1–7. [PMC free article] [PubMed] [Google Scholar]
- Garrido M. A., Perez P., Titus J. A., Valdayo M. J., Winkler D. F., Barbieri S. A., Wunderlich J. R., Segal D. M. Targeted cytotoxic cells in human peripheral blood lymphocytes. J Immunol. 1990 Apr 15;144(8):2891–2898. [PubMed] [Google Scholar]
- Jung G., Eberhard H. J. An in-vitro model for tumor immunotherapy with antibody heteroconjugates. Immunol Today. 1988 Sep;9(9):257–260. doi: 10.1016/0167-5699(88)91304-7. [DOI] [PubMed] [Google Scholar]
- Lebow L. T., Bonavida B. Purification and characterization of cytolytic and noncytolytic human natural killer cell subsets. Proc Natl Acad Sci U S A. 1990 Aug;87(16):6063–6067. doi: 10.1073/pnas.87.16.6063. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mezzanzanica D., Canevari S., Ménard S., Pupa S. M., Tagliabue E., Lanzavecchia A., Colnaghi M. I. Human ovarian carcinoma lysis by cytotoxic T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components. Int J Cancer. 1988 Apr 15;41(4):609–615. doi: 10.1002/ijc.2910410422. [DOI] [PubMed] [Google Scholar]
- Nitta T., Sato K., Yagita H., Okumura K., Ishii S. Preliminary trial of specific targeting therapy against malignant glioma. Lancet. 1990 Feb 17;335(8686):368–371. doi: 10.1016/0140-6736(90)90205-j. [DOI] [PubMed] [Google Scholar]
- Parham P. On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c mice. J Immunol. 1983 Dec;131(6):2895–2902. [PubMed] [Google Scholar]
- Wong J. T., Colvin R. B. Selective reduction and proliferation of the CD4+ and CD8+ T cell subsets with bispecific monoclonal antibodies: evidence for inter-T cell-mediated cytolysis. Clin Immunol Immunopathol. 1991 Feb;58(2):236–250. doi: 10.1016/0090-1229(91)90139-2. [DOI] [PubMed] [Google Scholar]
- Wong J. T., Pinto C. E., Gifford J. D., Kurnick J. T., Kradin R. L. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies. J Immunol. 1989 Nov 15;143(10):3404–3411. [PubMed] [Google Scholar]